Common immunodeficiency variable in adults

• Published in: Revista alergia Mexico (Tecamachalco, Pueblo, Mexico : 1993) Vol. 64; no. 4; pp. 452 - 462
• Main Authors: O'Farrill-Romanillos, Patricia María, Herrera-Sánchez, Diana Andrea, Hernández-Fernández, Cecilia, López-Rocha, Eunice Giselle
• Format: Journal Article
• Language: English; Spanish
• Published: Mexico Colegio Mexicano de Inmunología Clínica y Alergia, A.C 01.12.2017
• Subjects: Adultos; Inmunodeficiencia común variable; Inmunodeficiencias humorales; Antibody defects immunodeficiencies; Common variable immunodeficiency
• DOI: 10.29262/ram.v64i4.323
• ISSN: 0002-5151

Primary immunodeficiencies (PIDs) are low-incidence diseases caused by defects in genes involved in the development, maintenance, and regulation of the immune system. Common variable immunodeficiency (CVID) is the most common symptomatic immunodeficiency of adulthood. It has an approximate prevalence of 1 in 25 000-50 000 in the general population, with a delay in diagnosis between 6-7 years. The clinical manifestations of CVID constitute six main categories: infections, pulmonary complications, granulomatous or polyclonal lymphocytic disease, autoimmunity, gastrointestinal diseases and malignancy Most patients must have at least one of the following clinical manifestations (infection, autoimmunity, lymphoproliferation). However, the diagnosis of CVID can be conferred in asymptomatic patients, especially in familial cases. Secondary causes of hypogammaglobulinemia should be ruled out in any patient meeting the diagnostic criteria for CVID, as the treatment may be totally different from that required for CVID. Because CVID comprises a heterogeneous group of syndromes with poor primary antibody production, the potential number of entities within this group is unknown. Patients with CVID suffer from various complications that are considered prognostic. In the absence of clear guidelines for their search, it is recommended that lymphoproliferative disease, lung disease, liver disease and autoimmunity be investigated intentionally during the initial evaluation. The intervals in which they should be performed are not clear, but several evaluations may be required per year, according to the clinical evolution of the patient.